{"id":829723,"date":"2025-03-25T16:43:16","date_gmt":"2025-03-25T20:43:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\/"},"modified":"2025-03-25T16:43:16","modified_gmt":"2025-03-25T20:43:16","slug":"agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\/","title":{"rendered":"Agenus to Present New BOT\/BAL Data in Two Presentations at AACR 2025"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Agenus to Present New BOT\/BAL Data in Two Presentations at AACR 2025<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nFirst oral presentation of BOT\/BAL neoadjuvant results from the NEOASIS trial in MSI-H and MSS solid tumors\n<\/li>\n<li>\nNew data from the treatment-refractory hepatocellular carcinoma (HCC) cohort of the BOT\/BAL Phase 1 trial to be presented\n<\/li>\n<\/ul>\n<p>LEXINGTON, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<b>Agenus Inc.<\/b> (Nasdaq: AGEN), a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25\u201330, 2025 in Chicago, Illinois. The presentations continue to build momentum for Agenus\u2019 neoadjuvant immunotherapy program with botensilimab and balstilimab (BOT\/BAL), including an oral presentation of the initial results from the NEOASIS trial in solid tumors and a poster featuring new data from the advanced hepatocellular carcinoma (HCC) cohort of a Phase 1 study evaluating BOT\/BAL in patients with advanced solid tumors. Data from two separate, independent studies of neoadjuvant treatment with BOT\/BAL in colorectal cancer&#8211;UNICORN and NEST&#8211; were presented earlier this year at ASCO-GI.\n<\/p>\n<p><b><span class=\"bwuline\">Oral Presentation Details:<\/span><\/b><\/p>\n<p><b>Presentation Title:<\/b> Neoadjuvant botensilimab plus balstilimab in MMR proficient and deficient early-stage cancers: First results of the pan-cancer NEOASIS study (NCT06279130)<br \/>\n<br \/><b>Presenting Author: <\/b>Myriam Chalabi, MD, Netherlands Cancer Institute<br \/>\n<br \/><b>Session Title:<\/b> Aiming for Cure: Adjuvant and Neoadjuvant Approaches<br \/>\n<br \/><b>Session Date and Time:<\/b> 4\/28\/2025; 2:30:00 &#8211; 4:30:00 PM CT<br \/>\n<br \/><b>Abstract Presentation Number:<\/b> CT130\n<\/p>\n<p><b><span class=\"bwuline\">Poster Presentation Details:<\/span><\/b><\/p>\n<p><b>Presentation Title:<\/b> Results from a phase 1 study of botensilimab and balstilimab in treatment refractory hepatocellular carcinoma (NCT03860272)<br \/>\n<br \/><b>Presenting Author:<\/b> Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center<br \/>\n<br \/><b>Session Title:<\/b> Late-Breaking Research: Clinical Research 3<br \/>\n<br \/><b>Session Date and Time:<\/b> 4\/29\/2025; 2:00 &#8211; 5:00 PM CT<br \/>\n<br \/><b>Location<\/b>: Poster Section 53<br \/>\n<br \/><b>Poster Board Number:<\/b> 9<br \/>\n<br \/><b>Abstract Presentation Number:<\/b> LB365\n<\/p>\n<p><b>About Botensilimab (BOT)<\/b><\/p>\n<p>\nBotensilimab is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to \u201ccold\u201d tumors which generally respond poorly to standard of care or are refractory to conventional PD-1\/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.\n<\/p>\n<p>\nApproximately 1,100 patients have been treated with botensilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus\u2019 investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=54228473&amp;newsitemid=20250325174550&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=1&amp;md5=607c5601f913deaa3d13b00689afc32a\">www.clinicaltrials.gov<\/a> with the identifiers NCT03860272, NCT05608044, NCT05630183, and NCT05529316.\n<\/p>\n<p><b>About Balstilimab (BAL)<\/b><\/p>\n<p>\nBalstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in &gt;900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.\n<\/p>\n<p><b>About Agenus<\/b><\/p>\n<p>\nAgenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agenusbio.com&amp;esheet=54228473&amp;newsitemid=20250325174550&amp;lan=en-US&amp;anchor=www.agenusbio.com&amp;index=2&amp;md5=39d45d26f49cd1dd4f652a5c5491b8e2\">www.agenusbio.com<\/a> or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words &#8220;may,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;hopes,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;forecasts,&#8221; &#8220;estimates,&#8221; &#8220;will,&#8221; \u201cestablish,\u201d \u201cpotential,\u201d \u201csuperiority,\u201d \u201cbest in class,\u201d and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2023, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250325174550r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250325174550\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250325174550\/en\/<\/a><\/span><\/p>\n<p><b>Investors<br \/>\n<\/b><br \/>917-362-1370<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investor@agenusbio.com\">investor@agenusbio.com<\/a><\/p>\n<p><b>Media<br \/>\n<\/b><br \/>510-323-5188<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:communications@agenusbio.com\">communications@agenusbio.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Illinois Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Other Science Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250325174550\/en\/381089\/3\/2_Agenus-Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Agenus to Present New BOT\/BAL Data in Two Presentations at AACR 2025 First oral presentation of BOT\/BAL neoadjuvant results from the NEOASIS trial in MSI-H and MSS solid tumors New data from the treatment-refractory hepatocellular carcinoma (HCC) cohort of the BOT\/BAL Phase 1 trial to be presented LEXINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211;Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25\u201330, 2025 in Chicago, Illinois. The presentations continue to build momentum for Agenus\u2019 neoadjuvant immunotherapy program with botensilimab and balstilimab (BOT\/BAL), including an oral presentation of the initial results from the NEOASIS trial in solid tumors and a poster featuring new data from the advanced &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Agenus to Present New BOT\/BAL Data in Two Presentations at AACR 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-829723","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Agenus to Present New BOT\/BAL Data in Two Presentations at AACR 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agenus to Present New BOT\/BAL Data in Two Presentations at AACR 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Agenus to Present New BOT\/BAL Data in Two Presentations at AACR 2025 First oral presentation of BOT\/BAL neoadjuvant results from the NEOASIS trial in MSI-H and MSS solid tumors New data from the treatment-refractory hepatocellular carcinoma (HCC) cohort of the BOT\/BAL Phase 1 trial to be presented LEXINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211;Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25\u201330, 2025 in Chicago, Illinois. The presentations continue to build momentum for Agenus\u2019 neoadjuvant immunotherapy program with botensilimab and balstilimab (BOT\/BAL), including an oral presentation of the initial results from the NEOASIS trial in solid tumors and a poster featuring new data from the advanced &hellip; Continue reading &quot;Agenus to Present New BOT\/BAL Data in Two Presentations at AACR 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T20:43:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250325174550r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Agenus to Present New BOT\\\/BAL Data in Two Presentations at AACR 2025\",\"datePublished\":\"2025-03-25T20:43:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\\\/\"},\"wordCount\":805,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250325174550r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\\\/\",\"name\":\"Agenus to Present New BOT\\\/BAL Data in Two Presentations at AACR 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250325174550r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-03-25T20:43:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250325174550r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250325174550r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agenus to Present New BOT\\\/BAL Data in Two Presentations at AACR 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agenus to Present New BOT\/BAL Data in Two Presentations at AACR 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\/","og_locale":"en_US","og_type":"article","og_title":"Agenus to Present New BOT\/BAL Data in Two Presentations at AACR 2025 - Market Newsdesk","og_description":"Agenus to Present New BOT\/BAL Data in Two Presentations at AACR 2025 First oral presentation of BOT\/BAL neoadjuvant results from the NEOASIS trial in MSI-H and MSS solid tumors New data from the treatment-refractory hepatocellular carcinoma (HCC) cohort of the BOT\/BAL Phase 1 trial to be presented LEXINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211;Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25\u201330, 2025 in Chicago, Illinois. The presentations continue to build momentum for Agenus\u2019 neoadjuvant immunotherapy program with botensilimab and balstilimab (BOT\/BAL), including an oral presentation of the initial results from the NEOASIS trial in solid tumors and a poster featuring new data from the advanced &hellip; Continue reading \"Agenus to Present New BOT\/BAL Data in Two Presentations at AACR 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-25T20:43:16+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250325174550r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Agenus to Present New BOT\/BAL Data in Two Presentations at AACR 2025","datePublished":"2025-03-25T20:43:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\/"},"wordCount":805,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250325174550r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\/","name":"Agenus to Present New BOT\/BAL Data in Two Presentations at AACR 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250325174550r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-03-25T20:43:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250325174550r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250325174550r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-present-new-bot-bal-data-in-two-presentations-at-aacr-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Agenus to Present New BOT\/BAL Data in Two Presentations at AACR 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=829723"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829723\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=829723"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=829723"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=829723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}